Psoriasis Sponsor: Genentech, Inc.
A Phase IIIB, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXX in Adults with Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy.
September 2002 to January 2003
Psoriasis and Psoriatic Arthritis Sponsor: Amgen, Inc.
A Multicenter, Open-Label to Observe the Effects of XXXXX on Joint and Skin Disease in Subjects with Psoriatic Arthritis
July 2003 to August 2004